CD34 and hepatocellular carcinoma: A very recent study showed that higher pre-treatment levels of CD133+/CD34+/CD45dim cells (called circulating progenitor cells in that study) were associated with the worst outcome of suntinib therapy in hepatocellular carcinoma (Zhu et al, 2009).